Clinical Trial Update: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia [Phase 2]

View source ↗

Summary

Phase 2 trial of sotatercept in patients with myeloproliferative neoplasm-associated myelofibrosis or anemia has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Myeloproliferative Neoplasm
• Myelofibrosis

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Anemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2023-06-06